Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Pinto

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Molecules (Basel, Switzerland)|February 25, 2023
Discriminating Aroma Compounds in Five Cocoa Bean Genotypes from Two Brazilian States: White Kerosene-like Catongo, Red Whisky-like FL89 (Bahia), Forasteros IMC67, PA121 and P7 (Pará)Sonia Collin, Toine Fisette, Anne Pinto, et al.
Journal of Clinical Epidemiology|December 2, 2021
Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessmentTommi Tervonen, Thibaud Prawitz, Gin Nie Chua, et al.
Journal of Clinical Lipidology|February 12, 2015
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatinRonald M Krauss, Cathy Anne Pinto, Yang Liu, et al.
BMC Cancer|November 5, 2013
Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort studyCathy Anne Pinto, Stephen Marcella, David A August, et al.
The Patient|September 27, 2021
Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice ExperimentCathy Anne Pinto, Gin Nie Chua, John F P Bridges, et al.
Drug Discovery Today|July 19, 2023
Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvalsCathy Anne Pinto, Zaneta Balantac, Shahrul Mt-Isa, et al.
Future Oncology (London, England)|February 12, 2025
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experimentShawna R Calhoun, Caroline Vass, Kelley Myers, et al.
Future Oncology (London, England)|February 13, 2025
Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experimentCaroline Vass, Cathy Anne Pinto, Kelley Myers, et al.
BMC Medical Informatics and Decision Making|June 21, 2020
Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparisonChiara Whichello, Bennett Levitan, Juhaeri Juhaeri, et al.
Clinical Trials (London, England)|August 12, 2009
Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thicknessA Lawrence Gould, Joerg Koglin, Raymond P Bain, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Molecules (Basel, Switzerland)|February 25, 2023
Discriminating Aroma Compounds in Five Cocoa Bean Genotypes from Two Brazilian States: White Kerosene-like Catongo, Red Whisky-like FL89 (Bahia), Forasteros IMC67, PA121 and P7 (Pará)Sonia Collin, Toine Fisette, Anne Pinto, et al.
Journal of Clinical Epidemiology|December 2, 2021
Net clinical benefit of antiplatelet therapy was affected by patient preferences: A personalized benefit-risk assessmentTommi Tervonen, Thibaud Prawitz, Gin Nie Chua, et al.
Journal of Clinical Lipidology|February 12, 2015
Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatinRonald M Krauss, Cathy Anne Pinto, Yang Liu, et al.
BMC Cancer|November 5, 2013
Cardiopulmonary bypass has a modest association with cancer progression: a retrospective cohort studyCathy Anne Pinto, Stephen Marcella, David A August, et al.
The Patient|September 27, 2021
Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice ExperimentCathy Anne Pinto, Gin Nie Chua, John F P Bridges, et al.
Drug Discovery Today|July 19, 2023
Regulatory benefit-risk assessment of oncology drugs: A systematic review of FDA and EMA approvalsCathy Anne Pinto, Zaneta Balantac, Shahrul Mt-Isa, et al.
Future Oncology (London, England)|February 12, 2025
Patient preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experimentShawna R Calhoun, Caroline Vass, Kelley Myers, et al.
Future Oncology (London, England)|February 13, 2025
Oncologists' and urologists' preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experimentCaroline Vass, Cathy Anne Pinto, Kelley Myers, et al.
BMC Medical Informatics and Decision Making|June 21, 2020
Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparisonChiara Whichello, Bennett Levitan, Juhaeri Juhaeri, et al.
Clinical Trials (London, England)|August 12, 2009
Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thicknessA Lawrence Gould, Joerg Koglin, Raymond P Bain, et al.
Pageof 4